<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:identifier>http://www.wikidata.org/entity/Q37087332</dc:identifier>
  <dc:identifier>doi:10.1155/2008/727505</dc:identifier>
  <dc:title>Antibiotic resistance patterns in invasive group B streptococcal isolates</dc:title>
  <dc:creator>Castor, Mei L</dc:creator>
  <dc:creator>Whitney, Cynthia G</dc:creator>
  <dc:creator>Como-Sabetti, Kathryn</dc:creator>
  <dc:creator>Facklam, Richard R</dc:creator>
  <dc:creator>Ferrieri, Patricia</dc:creator>
  <dc:creator>Bartkus, Joanne M</dc:creator>
  <dc:creator>Juni, Billie A</dc:creator>
  <dc:creator>Cieslak, Paul R</dc:creator>
  <dc:creator>Farley, Monica M</dc:creator>
  <dc:creator>Dumas, Nellie B</dc:creator>
  <dc:creator>Schrag, Stephanie J</dc:creator>
  <dc:creator>Lynfield, Ruth</dc:creator>
  <dc:type>journal article</dc:type>
  <dc:date>2008-01-01</dc:date>
  <dc:language>en</dc:language>
  <dc:rights>http://creativecommons.org/licenses/by/3.0/</dc:rights>
  <dc:subject>antibiotic resistance</dc:subject>
  <dc:publisher>Hindawi Limited</dc:publisher>
  <dc:description>&lt;jats:p&gt;Antibiotics are used for both group B streptococcal (GBS) prevention and treatment. Active population-based surveillance for invasive GBS disease was conducted in four states during 1996â€”2003. Of 3813 case-isolates, 91.0% (3471) were serotyped, 77.1% (2937) had susceptibility testing, and 46.6% (3471) had both. All were sensitive to penicillin, ampicillin, cefazolin, cefotaxime, and vancomycin. Clindamycin and erythromycin resistance was 12.7% and 25.6%, respectively, and associated with serotype V (&lt;mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"&gt;&lt;mml:mi&gt;P&lt;/mml:mi&gt;&lt;mml:mo&gt;&lt;&lt;/mml:mo&gt;&lt;mml:mn&gt;.001&lt;/mml:mn&gt;&lt;/mml:math&gt;). Clindamycin resistance increased from 10.5% to 15.0% (&lt;mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"&gt;&lt;mml:msup&gt;&lt;mml:mi&gt;X&lt;/mml:mi&gt;&lt;mml:mn&gt;2&lt;/mml:mn&gt;&lt;/mml:msup&gt;&lt;/mml:math&gt;for trend 12.70;&lt;mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"&gt;&lt;mml:mi&gt;P&lt;/mml:mi&gt;&lt;mml:mo&gt;&lt;&lt;/mml:mo&gt;&lt;mml:mn&gt;.001&lt;/mml:mn&gt;&lt;/mml:math&gt;); inducible clindamycin resistance was associated with the&lt;jats:italic&gt;erm&lt;/jats:italic&gt;genotype. Erythromycin resistance increased from 15.8% to 32.8% (&lt;mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"&gt;&lt;mml:msup&gt;&lt;mml:mi&gt;X&lt;/mml:mi&gt;&lt;mml:mn&gt;2&lt;/mml:mn&gt;&lt;/mml:msup&gt;&lt;/mml:math&gt;for trend 55.46;&lt;mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"&gt;&lt;mml:mi&gt;P&lt;/mml:mi&gt;&lt;mml:mo&gt;&lt;&lt;/mml:mo&gt;&lt;mml:mn&gt;.001&lt;/mml:mn&gt;&lt;/mml:math&gt;). While GBS remains susceptible to beta-lactams, resistance to alternative agents such as erythromycin and clindamycin is an increasing concern.&lt;/jats:p&gt;</dc:description>
</oai_dc:dc>